Abemaciclib is used together with tamoxifen or an aromatase inhibitor (eg, anastrozole, exemestane, letrozole) to treat hormone receptor (HR)-positive, HER-2 negative, node-positive, early breast cancer with a high risk of coming back as determined by your doctor.
Abemaciclib, sold under the brand name Verzenio among others, is a medication for the treatment of advanced or metastatic breast cancers. It was developed by Eli Lilly and it acts as a CDK inhibitor selective for CDK4 and CDK6.
Abemaciclib is used to treat HR-positive and HER2-negative breast cancer in adults. It is a targeted treatment, not a chemotherapy drug (see Is Verzenio (abemaciclib) a chemo drug?). Abemaciclib (brand name Verzenio) first gained FDA approval on . There is no generic Verzenio.
Abemaciclib works by blocking the activity of proteins called CDK4 and CDK6 that control how fast cells grow. Blocking these proteins may slow or stop the growth of cancer cells.
The absolute bioavailability of abemaciclib after a single oral dose of 200 mg is 45% (19% CV). The median Tmax of abemaciclib is 8.0 hours (range: 4.1-24.0 hours).
Abemaciclib is used to treat locally advanced or advanced (metastatic) breast cancer. It may also be given for early breast cancer that has a higher risk of coming back.
Abemaciclib is used in combination with tamoxifen (Soltamox) or an aromatase inhibitor such as anastrozole (Arimidex), exemestane (Aromasin), or letrozole (Femara) to treat a certain type of hormone receptor-positive, early breast cancer.
Abemaciclib is a medication used to treat HR+ HER2- advanced or metastatic breast cancer. Abemaciclib is an antitumor agent and dual inhibitor of cyclin-dependent kinases 4 (CDK4) and 6 (CDK6) that are involved in the cell cycle and promotion of cancer cell growth in case of unregulated activity.